## Clinical Practice Guidelines: **Pre-malignant** Lesions of Anal Area (1/2)

Patients with dysplasia should be followed at regular intervals (variety of methods) 2B



Screening with Anal Pap can be considered in high risk pts (but not for universal screening) 2B



HRA can be considered for screening when performed by someone with appropriate training (2B)




**Topical agents** are options for treatment of **LSIL or HSIL** (2B)



Ablative treatment (with conventional anoscopy or HRA) is appropriate for HSIL (2B)

Vaccination against HPV (age <26) for primary prevention is recommended (2A)







Stewart DB et al. Dis Colon Rectum 2018;61(7):755-74